2/4/2013

SNMMI and other supporters of the PET imaging agent Amyvid are calling on CMS to provide coverage of the agent for diagnosis of Alzheimer's disease. The move follows a Medicare Evidence Development and Coverage Advisory Committee hearing where the panel questioned the utility of Amyvid in improving health outcomes. SNMMI said clinical evidence and FDA approval of the agent back "the ability of beta-amyloid imaging to change patient management, leading to better outcomes for patients."

Full Story:
DOTMed.com

Related Summaries